Genomic-metabolomic personalized diet,
does it really help with Greater fat-mass loss than a generic healthy diet?
research showsThe grade is D with 30 points. In PREVENTOMICS, 10-week fat-mass change was -2.1 kg with personalization and -2.0 kg with a generic healthy diet; the adjusted between-group difference was -0.1 kg (95% CI -1.2 to 0.9, P=.77). Both groups lost weight, but omics-based personalization added no benefit.
ads claimThe platform genuinely classified metabolic profiles and changed advice, but that added personalization did not reduce fat mass more than the healthy control diet.
Useful facts when choosing a product
- The platform used 51 blood and urine metabolic biomarkers and 35 salivary SNPs.
- Both groups received 12 of 21 weekly meals free for 10 weeks without instructions to restrict calories.
- PMID 35351696 is the protocol and PMID 35839545 the main result; both report NCT04590989.
Chamgap Semantic Classification Code
Candidate index · review held
D.diet-personalized-with-genomic-and-metabolomic-testing.dietary.greater-fat-mass-loss-than-a-generic-healthy-diet.assess.UNKDietary patterns and eating practices > Diet personalized with genomic and metabolomic testing > Dietary regimen > Greater fat-mass loss than a generic healthy diet > Association or change assessment > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
This single-center Danish double-blind parallel trial randomized 100 participants, 49 versus 51. The BMJ Open protocol and Clinical Nutrition results are reports from the same NCT04590989 trial and count once. Primary fat-mass analysis used available data from 82 participants, 38 versus 44, excluding 18%. Enrollment below 200, 10-week duration, attrition above 15%, and available-data rather than complete randomized-group preservation are limitations. Public and university funding from EU Horizon 2020 and a university scholarship was confirmed.
Why this is classified as D (30)
The prespecified primary fat-mass outcome showed no personalization advantage in a single 100-person 10-week trial, giving D with 30 points.
Counterpoint. Other algorithms, longer follow-up, or prospectively specified biological subgroups remain separate questions.
Rejudgment record. Cross-check applied — Cross-checked NCT04590989, the BMJ Open protocol, and Clinical Nutrition results for one-trial identity, primary endpoint, 82-person analysis, interval, and public funding
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduces fat mass more than a generic healthy diet | D | The adjusted difference was -0.1 kg and the interval included zero. |
| Weight loss within both healthy-diet programs | C | Both groups lost weight, but no untreated control separated a common program effect. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Aldubayan MA, Pigsborg K, Gormsen SMO, Serra F, Palou M, Galmés S, Palou-March A, Favari C, Wetzels M, Calleja A, Rodríguez Gómez MA, Castellnou MG, Caimari A, Galofré M, Suñol D, Escoté X, Alcaide-Hidalgo JM, M Del Bas J, Gutierrez B, Krarup T, Hjorth MF, Magkos F. 2022 PREVENTOMICS | Single-center double-blind randomized parallel trial; same trial as the BMJ Open protocol | 100 randomized (49/51), with 82 in the primary available-data analysis (38/44) | EU Horizon 2020 grant 818318 and a King Saud bin Abdulaziz University PhD scholarship | Change in DXA fat mass at 10 weeks | -2.1 vs -2.0 kg; adjusted between-group difference -0.1 kg (95% CI -1.2 to 0.9), P=.77 | Single publicly funded null trial on the prespecified primary endpoint |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-17).
Final verification and publication gate: Codex · Evidence date: 2026-08-17 · Corrections: none
Cite this verdict
[Chamgap] Genomic-metabolomic personalized diet x fat-mass reduction — Evidence Grade D·30. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/genomic-metabolomic-personalized-diet-fat-mass/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.